Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Clin Liver Dis. 2011 Aug;15(3):641-56. doi: 10.1016/j.cld.2011.05.008.

Hepatitis C therapy: other players in the game.

Author information

  • 1Loyola University Medical Center, Maywood, IL 60153, USA.

Abstract

Therapies in addition to the direct-acting antiviral agents (DAA) under evaluation for chronic hepatitis C include host targets such as cyclophilin inhibitors and immunomodulators. Both passive and therapeutic vaccines hold promise for the future. Although the numbers of drug categories and individual agents are increasing, only a handful of the non-DAAs seem to be ready to move on to phase III trials. New interferon agents are in development, and ribavirin variants are still under consideration. The role of the other players in the overall armamentarium against hepatitis C virus is still evolving.

Copyright © 2011 Elsevier Inc. All rights reserved.

PMID:
21867942
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk